← All sarcoma trials
Opening soonPhase 2Ages 18 Years and up

Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors

Sponsor: Charite University, Berlin, Germany · NCT04889742 on ClinicalTrials.gov ↗

Conditions studied

Recurrent CancerProstate CancerCervical CancerAnal CancerSarcomaRectal CancerNeuroendocrine TumorsEsophageal CancerPancreas CancerSquamous Cell Carcinoma

What it tests

  • loco-regional hyperthermiadevice

Where it's running1 site

1 international site
  • Klinik für Radioonkologie und Strahlentherapie

    Berlin, Germany 13353

    • Sebastian Zschaeck, M.D.(contact)
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* prior radiotherapy of the treatment side with a treatment dose \> 30 Gray (Gy) EQD2 (calculated with alpha/beta value of 9)
* local/ regional / or oligometastatic tumor recurrence. Maximum number of three macroscopic tumor lesions with at least one of them receiving prior radiotherapy
* macroscopic tumor recurrence
* side of recurrence is amenable to hyperthermia (abdomen, pelvis, extremities, spine, cervical lymphnodes)
* planned re-irradiation dose of at least 40 Gy EQD2 (calculated with alpha/beta value of 9)

Exclusion Criteria:

* \>3 macroscopic tumor lesion
* brain metastases
* recurrence is amenable to local ablative radiotherapy (brachytherapy or stereotactic radiotherapy)
* recurrence region is not amenable to hyperthermia (lung, liver, mediastinum)
* contraindications for hyperthermia (serious cariovascular disease, ICD or larger implants at the treatment site)
* psychiatric disorders that impede proper informed consent
* serious comorbidities with very limited prognosis quo ad vitam

Updated 2023-12-26 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.